

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 April 2009 (02.04.2009)

PCT

(10) International Publication Number
WO 2009/042970 A1

(51) International Patent Classification:

C07C 311/48 (2006.01) *A61K 31/235* (2006.01)
C07D 333/34 (2006.01) *A61K 31/5377* (2006.01)
C07D 295/192 (2006.01) *A61P 9/04* (2006.01)
A61K 31/18 (2006.01) *A61P 9/10* (2006.01)
A61K 31/192 (2006.01) *C07D 333/38* (2006.01)

(21) International Application Number:

PCT/US2008/078024

(22) International Filing Date:

26 September 2008 (26.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/995,636 26 September 2007 (26.09.2007) US

(71) Applicants (for all designated States except US): **JOHNS HOPKINS UNIVERSITY** [US/US]; 5th Floor, 100 N. Charles Street, Baltimore, MD 21201 (US). **CARDIOXYL PHARMACEUTICALS, INC.** [US/US]; Suite 501, 40 York Road, Towson, MD 21204-5243 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TOSCANO, John, P.** [US/US]; 18 Tree Farm Court, Glen Arm, MD 21057 (US). **BROOKFIELD, Frederick, Arthur** [GB/GB]; 114 Milton Park, Abingdon, Oxfordshire OX14 4SA (GB). **COHEN, Andrew, D.** [US/US]; Apt. 28A, 345 East

80th Street, New York, NY 10021 (US). **COURTNEY, Stephen, Martin** [GB/GB]; 114 Milton Park, Abingdon, Oxfordshire OX14 4SA (GB). **FROST, Lisa, Marie** [GB/GB]; 114 Milton Park, Abingdon, Oxfordshire OX14 4SA (GB). **KALISH, Vincent, Jacob** [US/US]; 344 Dubois Road, Annapolis, MD 21401 (US).




(74) Agents: **REANEY, Shannon** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: *N*-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS



(57) Abstract: The invention relates to *N*-hydroxylsulfonamide derivatives for formula (I), (II) or (III), in which the variables are as defined in the claims, that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. *N*-hydroxylsulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of the functional groups on the *N*-hydroxylsulfonamide derivatives.

WO 2009/042970 A1



Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*